Baby born in Hawaii with brain damage confirmed to have Zika infection

Before you go, we thought you'd like these...
Before you go close icon
Pregnant Women Warned to Avoid Travel to Brazil Due to Zika Virus

A baby born with brain damage at a hospital in Oahu, Hawaii, has been confirmed to have been infected by the Zika virus, that state's department of health said, in what appears to be the first U.S. case of the mosquito-borne virus.

The Hawaii State Department of Health said in a written statement that the mother was believed to have had a Zika infection while living in Brazil in May 2015 and that the baby was likely infected in the womb.

"We are saddened by the events that have affected this mother and her newborn," Dr. Sarah Park, Hawaii state epidemiologist, said in the statement.

RELATED: Other mosquito-borne viruses:

14 PHOTOS
New mosquito-borne virus spreads in Latin America
See Gallery
Baby born in Hawaii with brain damage confirmed to have Zika infection
TO GO WITH AFP STORY by Natalia Ramos A researcher examines transgenic Aedes aegypti mosquitos kept in cages to collect their eggs, at a laboratory of biotech company Oxitec, in Campinas, 100 km from Sao Paulo, Brazil, on August 21, 2014. Oxitec produces genetically modified mosquitoes to fight dengue, a deadly tropical disease more prevalent in Brazil than anywhere else in the world. The factory developed a technology where eggs of Aedes aegypti receive microinjection of DNA with genes that produce a protein which prevents their offsprings from reaching adulthood and thus reducing the total population of transmitters of dengue. AFP PHOTO / NELSON ALMEIDA (Photo credit should read NELSON ALMEIDA/AFP/Getty Images)
TO GO WITH AFP STORY by Natalia Ramos Transgenic Aedes aegypti mosquitos are kept in cages for reserachers to collect their eggs, at a laboratory of biotech company Oxitec, in Campinas, 100 km from Sao Paulo, Brazil, on August 21, 2014. Oxitec produces genetically modified mosquitoes to fight dengue, a deadly tropical disease more prevalent in Brazil than anywhere else in the world. The factory developed a technology where eggs of Aedes aegypti receive microinjection of DNA with genes that produce a protein which prevents their offsprings from reaching adulthood and thus reducing the total population of transmitters of dengue. AFP PHOTO / NELSON ALMEIDA (Photo credit should read NELSON ALMEIDA/AFP/Getty Images)
TO GO WITH AFP STORY by Natalia Ramos A researcher examines transgenic Aedes aegypti mosquitos kept in cages to collect their eggs, at a laboratory of biotech company Oxitec, in Campinas, 100 km from Sao Paulo, Brazil, on August 21, 2014. Oxitec produces genetically modified mosquitoes to fight dengue, a deadly tropical disease more prevalent in Brazil than anywhere else in the world. The factory developed a technology where eggs of Aedes aegypti receive microinjection of DNA with genes that produce a protein which prevents their offsprings from reaching adulthood and thus reducing the total population of transmitters of dengue. AFP PHOTO / NELSON ALMEIDA (Photo credit should read NELSON ALMEIDA/AFP/Getty Images)
TO GO WITH AFP STORY by Natalia Ramos Transgenic Aedes aegypti mosquitos are kept in cages for reserachers to collect their eggs, at a laboratory of biotech company Oxitec, in Campinas, 100 km from Sao Paulo, Brazil, on August 21, 2014. Oxitec produces genetically modified mosquitoes to fight dengue, a deadly tropical disease more prevalent in Brazil than anywhere else in the world. The factory developed a technology where eggs of Aedes aegypti receive microinjection of DNA with genes that produce a protein which prevents their offsprings from reaching adulthood and thus reducing the total population of transmitters of dengue. AFP PHOTO / NELSON ALMEIDA (Photo credit should read NELSON ALMEIDA/AFP/Getty Images)
TO GO WITH AFP STORY by Natalia Ramos A researcher collects eggs of transgenic Aedes aegypti mosquitos, at a laboratory of biotech company Oxitec, in Campinas, 100 km from Sao Paulo, Brazil, on August 21, 2014. Oxitec produces genetically modified mosquitoes to fight dengue, a deadly tropical disease more prevalent in Brazil than anywhere else in the world. The factory developed a technology where eggs of Aedes aegypti receive microinjection of DNA with genes that produce a protein which prevents their offsprings from reaching adulthood and thus reducing the total population of transmitters of dengue. AFP PHOTO / NELSON ALMEIDA (Photo credit should read NELSON ALMEIDA/AFP/Getty Images)
TO GO WITH AFP STORY by Natalia Ramos A researcher collects eggs of transgenic Aedes aegypti mosquitos, at a laboratory of biotech company Oxitec, in Campinas, 100 km from Sao Paulo, Brazil, on August 21, 2014. Oxitec produces genetically modified mosquitoes to fight dengue, a deadly tropical disease more prevalent in Brazil than anywhere else in the world. The factory developed a technology where eggs of Aedes aegypti receive microinjection of DNA with genes that produce a protein which prevents their offsprings from reaching adulthood and thus reducing the total population of transmitters of dengue. AFP PHOTO / NELSON ALMEIDA (Photo credit should read NELSON ALMEIDA/AFP/Getty Images)
TO GO WITH AFP STORY by Natalia Ramos Larvae of transgenic Aedes aegypti mosquitos are pictured through a microscope viewfinder at a laboratory of biotech company Oxitec, in Campinas, 100 km from Sao Paulo, Brazil, on August 21, 2014. Oxitec produces genetically modified mosquitoes to fight dengue, a deadly tropical disease more prevalent in Brazil than anywhere else in the world. The factory developed a technology where eggs of Aedes aegypti receive microinjection of DNA with genes that produce a protein which prevents their offsprings from reaching adulthood and thus reducing the total population of transmitters of dengue. AFP PHOTO / NELSON ALMEIDA (Photo credit should read NELSON ALMEIDA/AFP/Getty Images)
TO GO WITH AFP STORY by Natalia Ramos Larvae of transgenic Aedes aegypti mosquitos are pictured through a microscope viewfinder at a laboratory of biotech company Oxitec, in Campinas, 100 km from Sao Paulo, Brazil, on August 21, 2014. Oxitec produces genetically modified mosquitoes to fight dengue, a deadly tropical disease more prevalent in Brazil than anywhere else in the world. The factory developed a technology where eggs of Aedes aegypti receive microinjection of DNA with genes that produce a protein which prevents their offsprings from reaching adulthood and thus reducing the total population of transmitters of dengue. AFP PHOTO / NELSON ALMEIDA (Photo credit should read NELSON ALMEIDA/AFP/Getty Images)
TO GO WITH AFP STORY by Natalia Ramos Transgenic Aedes aegypti mosquitos are seen in a container at a laboratory of biotech company Oxitec, in Campinas, 100 km from Sao Paulo, Brazil, on August 21, 2014. Oxitec produces genetically modified mosquitoes to fight dengue, a deadly tropical disease more prevalent in Brazil than anywhere else in the world. The factory developed a technology where eggs of Aedes aegypti receive microinjection of DNA with genes that produce a protein which prevents their offsprings from reaching adulthood and thus reducing the total population of transmitters of dengue. AFP PHOTO / NELSON ALMEIDA (Photo credit should read NELSON ALMEIDA/AFP/Getty Images)
TO GO WITH AFP STORY by Natalia Ramos Transgenic Aedes aegypti mosquitos are seen in containers at a laboratory of biotech company Oxitec, in Campinas, 100 km from Sao Paulo, Brazil, on August 21, 2014. Oxitec produces genetically modified mosquitoes to fight dengue, a deadly tropical disease more prevalent in Brazil than anywhere else in the world. The factory developed a technology where eggs of Aedes aegypti receive microinjection of DNA with genes that produce a protein which prevents their offsprings from reaching adulthood and thus reducing the total population of transmitters of dengue. AFP PHOTO / NELSON ALMEIDA (Photo credit should read NELSON ALMEIDA/AFP/Getty Images)
TO GO WITH AFP STORY by Natalia Ramos The production supervisor of biotech company Oxitec, Sofia Bastos Pinto, looks at transgenic Aedes aegypti mosquitos kept in a container at the lab in Campinas, 100 km from Sao Paulo, Brazil, on August 21, 2014. Oxitec produces genetically modified mosquitoes to fight dengue, a deadly tropical disease more prevalent in Brazil than anywhere else in the world. The factory developed a technology where eggs of Aedes aegypti receive microinjection of DNA with genes that produce a protein which prevents their offsprings from reaching adulthood and thus reducing the total population of transmitters of dengue. AFP PHOTO / NELSON ALMEIDA (Photo credit should read NELSON ALMEIDA/AFP/Getty Images)
TO GO WITH AFP STORY by Natalia Ramos The production supervisor of biotech company Oxitec, Sofia Bastos Pinto, looks at transgenic Aedes aegypti mosquitos through a microscope at the lab in Campinas, 100 km from Sao Paulo, Brazil, on August 21, 2014. Oxitec produces genetically modified mosquitoes to fight dengue, a deadly tropical disease more prevalent in Brazil than anywhere else in the world. The factory developed a technology where eggs of Aedes aegypti receive microinjection of DNA with genes that produce a protein which prevents their offsprings from reaching adulthood and thus reducing the total population of transmitters of dengue. AFP PHOTO / NELSON ALMEIDA (Photo credit should read NELSON ALMEIDA/AFP/Getty Images)
TO GO WITH AFP STORY by Natalia Ramos The production supervisor of biotech company Oxitec, Sofia Bastos Pinto, looks at larvae of transgenic Aedes aegypti mosquitos kept in trays at the lab in Campinas, 100 km from Sao Paulo, Brazil, on August 21, 2014. Oxitec produces genetically modified mosquitoes to fight dengue, a deadly tropical disease more prevalent in Brazil than anywhere else in the world. The factory developed a technology where eggs of Aedes aegypti receive microinjection of DNA with genes that produce a protein which prevents their offsprings from reaching adulthood and thus reducing the total population of transmitters of dengue. AFP PHOTO / NELSON ALMEIDA (Photo credit should read NELSON ALMEIDA/AFP/Getty Images)
HIDE CAPTION
SHOW CAPTION
of
SEE ALL
BACK TO SLIDE

On Friday U.S. health officials issued a travel warning for 14 countries and territories in the Caribbean and Latin America where infection with Zika is a risk.

The U.S. Centers for Disease Control and Prevention (CDC) in particular cautioned pregnant women not to travel to those areas as Zika has been linked to serious birth defects. (www.cdc.gov/zika/index.html)

The travel alert applies to Brazil, Colombia, El Salvador, French Guiana, Guatemala, Haiti, Honduras, Martinique, Mexico, Panama, Paraguay, Suriname, Venezuela, and the U.S. Commonwealth of Puerto Rico.

It also includes advice that women who are trying to become pregnant should consult with their doctor before traveling to those areas.

READ ALSO: Life-threatening weather headed for parts of the US

In the Hawaii case, a doctor recognized the possibility of a Zika infection in the newborn baby and alerted state officials, the health department said. The infection was confirmed by a laboratory test conducted by the U.S. Centers for Disease Control and Prevention.

The Hawaii health department said it sent a medical advisory about the infection to doctors across the state but emphasized that neither the mother nor baby were infectious.

Zika virus is transmitted by Aedes species mosquitoes, which also spread dengue and chikungunya viruses and are common in Texas, Florida and elsewhere in the United States.

The virus is usually a mild illness with fever, rash and joint pain. There is no preventive vaccine or treatment, according to the CDC.

More on AOL.com:
Report: Jailed US reporter among 5 prisoners released
Donald Trump goes ballistic on Cruz, invokes 9/11​
Dying 8-year-old's unusual wish captivates China

Read Full Story

Sign up for Breaking News by AOL to get the latest breaking news alerts and updates delivered straight to your inbox.

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners